Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment is anchored in long-established regimens, including interferons (pegylated interferon α2a and α2b) and nucleoside analogues such as entecavir (Baraclude), tenofovir disoproxil fumarate (Viread), tenofovir alafenamide (Vemlidy), and tenofovir amibufenamide (Hengmu). These therapies dominate clinical practice due to strong physician familiarity, robust long-term evidence, and consistency with national guideline recommendations. Over the next 10 years, late-phase pipeline assets and policy shifts are expected to introduce greater diversification in treatment approaches. Potential developments include label expansions for interferon-based stimulants and broader use of combination regimens, particularly for patients with HBV coinfection. This report analyzes China’s evolving HBV treatment landscape and assesses how ongoing regulatory reforms, NRDL dynamics, and expanding VBP considerations may shape the launch environment, pricing expectations, and uptake trajectories for both current and emerging therapies.
QUESTIONS ANSWERED
- What is the diagnosed prevalence of HBV, and how are these patients treated today?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of HBV in China?
- What are the key market access considerations for therapies in the HBV pipeline in China?
- What are the key drivers of and constraints in China’s HBV therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
Release date: May 2026
Geography:China (urban / rural)
Primary research: Qualitative and quantitative insights driven from 5 thought-leader interviews and surveys with 50 gastroenterologists and hepatologists
Epidemiology: Diagnosed prevalence of HBV in urban versus rural China, clinically and commercially relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key therapies through 2035, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments: Coverage of key current and late-phase emerging therapies
Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)
